RT Journal Article
SR Electronic
T1 Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3727
DO 10.1183/13993003.congress-2021.PA3727
VO 58
IS suppl 65
A1 da Costa Martins, Sara Maria
A1 Tinoco, Eduarda
A1 Cabrita, Bruno
A1 Machado, Daniela
A1 Franco, Inês
A1 Ladeira, Inês
A1 Pascoal, Ivone
A1 Lima, Ricardo
A1 Valente, Salete
YR 2021
UL https://publications.ersnet.org//content/58/suppl_65/PA3727.abstract
AB Background: Nasal polyposis may impact asthma severity and is a frequent comorbidity in patients with severe eosinophilic asthma. Research has suggested mepolizumab may directly affect upper airway type 2 inflammatory conditions, however there is a lack of clinical studies confirming its effectiveness on nasal symptoms control.Aims: To assess the impact of mepolizumab on nasal symptoms control in patients with severe eosinophilic asthma and nasal polyposis.Methods: A multicenter retrospective study was performed in a cohort of patients with both nasal polyposis and severe refractory asthma treated with mepolizumab. Asthma-related parameters and sino-nasal clinical outcomes were analysed in baseline and 6-12 months after treatment initiation.Results: Twelve patients were included with an average age of 59 years at the start of mepolizumab therapy. The participants were predominantly females (75%) and 58% had history of sinus surgery. After at least 6 months of treatment with mepolizumab, effective control of asthma-related clinical parameters was observed, with a reduction in moderate to severe exacerbations and systemic corticosteroid therapy. In parallel, there was also a statistically significant improvement of sino-nasal symptoms and quality of life, evidenced by a reduction in the average total score on the Sino-Nasal Outcome Test 22, from 70 to 28 points (p= 0.008), and Nasal Congestion scale (range of severe symptoms (3) to mild (1), (p= 0.010)).Conclusions: Mepolizumab demonstrated clinical efficacy in controlling symptoms associated with nasal polyposis in patients with concomitant severe eosinophilic asthma, giving it the advantage of treating both conditions with the same intervention.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3727.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).